Sight Sciences, Inc. (SGHT) NASDAQ
4.38
-0.1625(-3.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.38
-0.1625(-3.58%)
Currency In USD
| Previous Close | 4.54 |
| Open | 4.51 |
| Day High | 4.89 |
| Day Low | 4.29 |
| 52-Week High | 9.24 |
| 52-Week Low | 3.11 |
| Volume | 117,132.09 |
| Average Volume | 320,944 |
| Market Cap | 238.18M |
| PE | -6.25 |
| EPS | -0.7 |
| Moving Average 50 Days | 4.3 |
| Moving Average 200 Days | 5.24 |
| Change | -0.16 |
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
GlobeNewswire Inc.
Feb 18, 2026 9:05 PM GMT
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to t
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights
GlobeNewswire Inc.
Jan 13, 2026 12:05 PM GMT
MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to t
New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans
GlobeNewswire Inc.
Nov 11, 2025 12:00 PM GMT
Prospective study data and retrospective registry data were analyzed in the manuscripts recently published by the Journal of Cataract and Refractive Surgery, Journal of Glaucoma and Clinical OphthalmologyMENLO PARK, Calif., Nov. 11, 2025 (GLOBE NEW